Hui Gong
Neurology · Los Angeles, CANPI 1316189426
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by SK Life Science, Inc. at 41.0% of the total. 2025 is the largest year on record at $531, 3.7 times the $143 reported in 2019.
Across 40 payments — averaging $41.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$687
- Livanova USA, Inc.$434
- UCB, Inc.$288
- Sumitomo Pharma America, Inc.$124
- Sunovion Pharmaceuticals Inc.$61
- TG Therapeutics, Inc.$32
- plus $52 from 2 others
Across 51 payments — averaging $6873.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$181K
- Aquestive Therapeutics, Inc.$105K
- Jazz Pharmaceuticals Inc.$21K
- SK Life Science, Inc.$20K
- Sunovion Pharmaceuticals Inc.$20K
- AbbVie$5K
What the payments were for
- Food & beverage$1,61796%
- Education$614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 8 | $687 |
| Livanova USA, Inc. | 22 | $434 |
| UCB, Inc. | 5 | $288 |
| Sumitomo Pharma America, Inc. | 1 | $124 |
| Sunovion Pharmaceuticals Inc. | 1 | $61 |
| TG Therapeutics, Inc. | 1 | $32 |
| Biogen | 1 | $28 |
| Greenwich Biosciences, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$125
- XCOPRI$125
- APTIOM$124
- VNS Therapy$119
How this compares
$1,678 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 23 | $2,117 |
| Levetiracetam | 12 | $1,310 |
| Clobazam | 11 | $357 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.